PRESS RELEASES Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 218 Results March 25, 2026 Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 March 12, 2026 Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum March 11, 2026 Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates March 4, 2026 Minerva Neurosciences to Participate in The Citizens Life Sciences Conference January 26, 2026 Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 November 19, 2025 Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors November 5, 2025 Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates October 21, 2025 Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved August 14, 2025 Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results May 13, 2025 Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates 12345...»